12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Company News  |  Deals

Aeterna Zentaris, Keryx deal

Aeterna and Keryx mutually terminated a deal that gave Keryx North American rights to Phase III cancer product perifosine ( KRX-0401). The move comes a month after perifosine missed the primary endpoint of median overall survival (OS) in the...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >